Idarucizumab for Dabigatran Reversal - Test2 - elhamkhani - TriplyDB

Idarucizumab for Dabigatran Reversal

Idarucizumab for Dabigatran Reversal

http://www.wikidata.org/entity/Q28263802

about

Reversal agents for NOACs: Connecting the dots Management of bleeding in patients treated with direct oral anticoagulants Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016 Dabigatran approaching the realm of heparin-induced thrombocytopenia Management of antithrombotic therapy during cardiac implantable device surgery Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians How we treat bleeding associated with direct oral anticoagulants Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues Edoxaban in venous thromboembolism and stroke prevention: an appraisal Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab Emerging Tools for Stroke Prevention in Atrial Fibrillation Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Perioperative atrial fibrillation: a systematic review of evolving therapeutic options in pharmacologic and procedural management Novel antidotes for target specific oral anticoagulants Postoperative atrial fibrillation in patients undergoing non-cardiac non-thoracic surgery: A practical approach for the hospitalist The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome The critical care management of spontaneous intracranial hemorrhage: a contemporary review Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention DOACs - advances and limitations in real world Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary Evidence Blood thinners and gastrointestinal endoscopy Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015 Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation Intracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing Controversies Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know Preclinical and clinical data for factor Xa and "universal" reversal agents Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.A Review of the Key Clinical Trials of 2015: Results and Implications Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review Evaluating the benefits of home-based management of atrial fibrillation: current perspectives Idarucizumab

P2860

Q26740248-9F09F0F8-43AC-4609-A6B9-32B5AB5812EB Q26740258-26C2C1B1-7889-413E-BDE0-C566234DEED8 Q26743727-985A4845-EF9B-4573-8351-C3537127FFF1 Q26744261-278734AA-9E6E-4BE7-904D-EF93066EF9DE Q26746160-227BA7FF-6C78-45CC-B3A1-B1E4ED472918 Q26746917-815A72E0-8122-4D90-AA52-19BA6A22778A Q26748343-4D0A262F-8A44-410B-B5E5-1EADC7ECFD60 Q26749141-DFA799D2-317A-4788-A10E-3852884B95BB Q26750767-A79DE9C5-5177-4906-9FD3-AB91F545DCA6 Q26751263-699D71DA-A9CD-4CCB-BD75-4ED5A9BB960A Q26764882-0B0A619E-1D27-420B-8D01-320BC3F0EC82 Q26765023-9F6A8FCA-C271-49E3-B1D8-4F289F7E2FBE Q26765949-BFB8166F-F1C2-47C0-9522-D7C4595481A1 Q26766303-6B0B4887-6010-4C0A-9F8A-1320500950D7 Q26770402-AB92D171-7558-409C-84DB-2EDDDA322B0B Q26776413-85CD9DB8-26AC-482E-A8EE-F6A7985540E7 Q26781769-B9467834-BBA3-4251-B3A8-16E795D0E767 Q26784125-C213319B-FA80-45E6-8FFA-CCC759C489C8 Q26785568-77AA3ED4-3F9D-47DD-81F5-A343F27DCE7D Q27339343-CBF81E1D-3A90-4732-BC31-E205E5783968 Q28066262-BED7462A-43BD-4199-BBA2-FA8205F727F9 Q28067420-DEFAAE9D-C2C6-4065-AB45-41E7C6B8762C Q28067962-F35E238F-0F51-43FA-944B-55EEAE43E3AB Q28069809-0F57150A-9F1A-4441-ABEE-7F629F4700B1 Q28070132-7C8543B6-768A-4D45-B5AF-1A9B98028C48 Q28071393-D1543FBB-8650-4922-BC68-DEBA18DBB5B6 Q28071595-44545218-7B89-4724-A940-4E52C21FDFBB Q28071657-16883494-ECD5-40DA-9A1C-47B0D4DCC0CF Q28072261-A6BC3F60-5201-4542-88CE-CB20A477A065 Q28072522-49E7FE76-E3A8-4EFA-B381-92CEA0733AF3 Q28073307-BFB856E0-8008-40E5-A737-081BC562FBEC Q28074445-E8C2AC44-C157-4081-A5F9-C231A4D94788 Q28075637-D67F5131-10A5-4BE3-8026-1D8031FB52A3 Q28076077-AA0A1833-8B1B-4525-8A4D-1EE5585ED11D Q28076774-BCD157D3-48A9-4F2C-9FCC-4F9424ACED25 Q28076902-13045C60-E219-4FCE-B7FA-525A2813ECDE Q28077170-6DDAEA88-C22F-4BA6-80C6-D48C5148899D Q28078177-39D31896-5424-4170-8CD6-419A40B00DAE Q28079137-40FF3BAC-4AAC-4A47-B185-DE556D0AD9ED Q28079302-4BD4465F-E697-4E2D-86A5-63BC76F68B01

P2860

Idarucizumab for Dabigatran Reversal

http://www.wikidata.org/entity/Q28263802

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Idarucizumab for Dabigatran Reversal

@ast

Idarucizumab for Dabigatran Reversal

@en

Idarucizumab for Dabigatran Reversal

@nl

type

label

Idarucizumab for Dabigatran Reversal

@ast

Idarucizumab for Dabigatran Reversal

@en

Idarucizumab for Dabigatran Reversal

@nl

prefLabel

Idarucizumab for Dabigatran Reversal

@ast

Idarucizumab for Dabigatran Reversal

@en

Idarucizumab for Dabigatran Reversal

@nl

P1433

Q28263802-6DD72E37-67A7-424A-A196-B6DF17D82AA7

P1476

Q28263802-924F8DC8-5D67-4C34-A8CD-7A4C858206C0

P2093

Q28263802-37495AB9-CCC4-42C8-967F-56B966A6D4CC

Q28263802-59B9ED8A-A8B3-4523-9DE7-783787650B65

Q28263802-6D9BD9E0-BCF4-4C0F-A602-7A90218BC476

Q28263802-7ADD4703-AA89-4933-9815-BED4DD493318

Q28263802-82BFF5FF-5804-4489-920D-163758A45680

Q28263802-830A31CA-D183-44B2-9FBF-6384FF42A3CC

Q28263802-8841F2DE-5E5A-4DC1-9E38-164023E21985

Q28263802-9793CD7F-5BEA-4970-A7D3-880927B3D5A1

Q28263802-9D04629C-08AA-47E6-8FE3-EF71ED890CEC

Q28263802-9E09D607-52E7-438A-B91B-B8FF0FA7DD69

P304

Q28263802-27CEFC09-158F-4767-8D67-DCF4336F5799

P31

Q28263802-AFC68013-118D-4640-9AB6-4C8F1488AFAA

P3181

Q28263802-12AFAB6B-FC5D-4754-9CAB-5E9AB41ACEAA

P356

Q28263802-A336570C-48A8-454D-B28C-7F7E7E298426

P407

Q28263802-7ED623FE-7D62-4D94-AE91-2FD5671D86E5

P433

Q28263802-447D6EA1-4DCC-4EBE-9472-2F3F711062EF

P478

Q28263802-B150958E-6800-46DB-8A05-8AF50BDCEBB9

P50

Q28263802-6FEE544B-2AA3-466E-979D-1E1E938A0D56

P577

Q28263802-8318476C-4FA9-44B2-8311-B04DE698ED5B

P698

Q28263802-055C9BFD-3FC9-4300-ADC6-ACC8842C6CA0

P3181

P356

P1433

The New England Journal of Medicine

P1476

Idarucizumab for Dabigatran Reversal

@en

P2093

Bushi Wang

http://www.w3.org/2001/XMLSchema#string

Chak-Wah Kam

http://www.w3.org/2001/XMLSchema#string

Charles V Pollack

http://www.w3.org/2001/XMLSchema#string

Elaine M Hylek

http://www.w3.org/2001/XMLSchema#string

Frank W Sellke

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Weitz

http://www.w3.org/2001/XMLSchema#string

Jerrold H Levy

http://www.w3.org/2001/XMLSchema#string

Joachim Stangier

http://www.w3.org/2001/XMLSchema#string

Jörg Kreuzer

http://www.w3.org/2001/XMLSchema#string

Menno V Huisman

http://www.w3.org/2001/XMLSchema#string

P304

511-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

451906

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1502000

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

John W. Eikelboom

P577

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26095746

http://www.w3.org/2001/XMLSchema#string